Lindbrook Capital’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-144
| Closed | -$14.7K | – | 2854 |
|
|
2023
Q2 | $14.7K | Sell |
144
-1
| -0.7% | -$95 | ﹤0.01% | 1250 |
|
|
2023
Q1 | $13.2K | Buy |
145
+66
| +84% | +$3.87K | ﹤0.01% | 1282 |
|
|
2022
Q4 | $3K | Buy |
79
+6
| +8% | +$206 | ﹤0.01% | 2054 |
|
|
2022
Q3 | $2K | Buy |
73
+24
| +49% | +$665 | ﹤0.01% | 2188 |
|
|
2022
Q2 | $1K | Buy |
49
+24
| +96% | +$716 | ﹤0.01% | 2435 |
|
|
2022
Q1 | $1K | Buy |
+25
| New | +$742 | ﹤0.01% | 2437 |
|
|
2021
Q4 | – | Sell |
-26
| Closed | -$3K | – | 2240 |
|
|
2021
Q3 | $3K | Sell |
26
-5
| -16% | -$586 | ﹤0.01% | 1470 |
|
|
2021
Q2 | $4K | Sell |
31
-18
| -37% | -$2.03K | ﹤0.01% | 1420 |
|
|
2021
Q1 | $5K | Hold |
49
| – | – | ﹤0.01% | 1291 |
|
|
2020
Q4 | $6K | Buy |
49
+29
| +145% | +$3.81K | ﹤0.01% | 1148 |
|
|
2020
Q3 | $2K | Buy |
+20
| New | +$2.5K | ﹤0.01% | 1471 |
|
|
2019
Q4 | – | Sell |
-400
| Closed | -$32K | – | 1566 |
|
|
2019
Q3 | $32K | Buy |
+400
| New | +$33.9K | 0.01% | 555 |
|
|
2019
Q2 | – | Sell |
-500
| Closed | -$43.2K | – | 1537 |
|
|
2019
Q1 | $42K | Sell |
500
-250
| -33% | -$20.8K | 0.02% | 472 |
|
|
2018
Q4 | $42K | Buy |
+750
| New | +$45.8K | 0.02% | 401 |
|
Other funds holding RETA
Lindbrook Capital's RETA Position: Q3 2023 in Review
Lindbrook Capital sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 144 shares — an estimated $14.7K sold.
Lindbrook Capital first reported a position in RETA in Q4 2018 and held it in 14 quarters. The position peaked at $42K in Q1 2019. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- Lindbrook Capital reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- Lindbrook Capital sold 144 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $14.7K.
- Lindbrook Capital first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2018 and held it in 14 quarters.
- Lindbrook Capital's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $42K in Q1 2019.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on Lindbrook Capital's 13F filing for Q3 2023, filed 25 Oct 2023.